Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis
The median times to MCID with ravulizumab treatment in patients with AChR Ab+ gMG were ~2 weeks and ~4 weeks based on MCID MG-ADL and QMG total score reductions, respectively.
Authors
- Tuan Vu (ORCID: https://orcid.org/0000-0003-0724-0210)
- Michael Benatar (ORCID: https://orcid.org/0000-0003-4241-5135)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Masahisa Katsuno (ORCID: https://orcid.org/0000-0001-9453-9311)
- Serena G. Liao
- Andreas Meisel (ORCID: https://orcid.org/0000-0001-7233-5342)
- Shahram Attarian (ORCID: https://orcid.org/0000-0002-7211-4694)
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
- Kathleen N. Beasley
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Miami (US)
- University of California, Irvine (US)
- Aix-Marseille Université (FR)
- University of South Florida (US)
- Alexion Pharmaceuticals (United States) (US)
- AstraZeneca (United States) (US)
- Nagoya University (JP)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1111/ene.16490
- Citations
- 10
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 3.69
Funders
- Alexion Pharmaceuticals